SynthesisFrontiers in oncology2026
Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors combined with chemotherapy have improved pathological responses in early-stage triple-negative breast cancer (TNBC), but the magnitude of benefit and associated toxicity remain variable across trials. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of immunotherapy plus chemotherapy in patients with early-stage or high-risk TNBC. Methods: This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to March 2026 for randomized controlled trials (RCTs). The primary outcome was pathological complete response (pCR). Dichotomous outcomes were pooled as risk ratios (RRs) with 95% confidence intervals (CIs). Between-study heterogeneity was assessed using Cochran's Q test and the I² statistic. Exploratory subgroup analyses were conducted according to programmed death-ligand 1 (PD-L1) expression and lymph node status. Results: Five RCTs were included. Immunotherapy plus chemotherapy was associated with a higher pCR rate than control regimens (RR = 1.44, 95% CI 1.09-1.79), with substantial heterogeneity (I² = 83.7%). In exploratory analyses, the pooled RR was 1.36 (95% CI 1.18-1.57) in PD-L1-positive patients and 1.18 (95% CI 0.96-1.45) in PD-L1-negative patients. Corresponding RRs were 1.42 (95% CI 1.19-1.69) for node-positive and 1.21 (95% CI 1.02-1.43) for node-negative disease. Immunotherapy-containing regimens were also associated with higher risks of grade 3-4 adverse events (RR = 1.18, 95% CI 1.05-1.33), serious adverse events (RR = 1.42, 95% CI 1.12-1.79), and treatment discontinuation due to adverse events (RR = 1.67, 95% CI 1.18-2.36). Conclusions: Immunotherapy combined with chemotherapy was associated with higher pCR rates in early-stage or high-risk TNBC but also with greater treatment-related toxicity. PD-L1 and nodal subgroup findings should be considered exploratory, and further evidence is needed to clarify long-term clinical outcomes. Systematic review registration: [url], identifier [].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.